Clinical trials: Perihilar Cholangiocarcinoma
Hilar Cholangiocarcinoma
Impact of Three-dimensional Visualization on Operation Strategy and Complications for Hilar Cholangiocarcinoma
The aim of the multi-centre study is to evaluate correctly the impact of three-dimensional visualization on operation strategy and complications for hilar cholangiocarcinoma.
- Trial name
- NCT03132649
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Zhujiang Hospital
Biliary Tract Cancer (BTC), Biliary Tract Cancer (CCA)
TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary Tract Cancer: a Real- World Cohort
Purpose of the Study: Bile duct cancers are rare and aggressive. About 250 new cases are diagnosed each year in Denmark. These cancers are difficult to detect early, so only about 20% of patients can have surgery when diagnosed.
- Conditions
- Biliary Tract Cancer (BTC), Biliary Tract Cancer (CCA), Gall Bladder Cancer, Biliary Tract Cancers (BTC)
- Trial name
- TRACE-BTC (NCT07454486)
- Where
- Denmark
- Volunteers
- 300 people
- Sponsor
- Aarhus University Hospital
Locally Advanced Perihilar Cholangiocarcinoma
A Prospective, Single-Arm, Phase II Study: PD-L1 Monoclonal Antibody + Chemoradiotherapy as Bridge Therapy to Liver Transplantation for Locally Advanced Perihilar Cholangiocarcinoma (ACHIEVE-LT)
This study is a prospective, single-arm, phase II clinical trial designed to evaluate the safety and efficacy of PD-L1 monoclonal antibody combined with chemoradiotherapy as a bridge to liver transplantation in patients with…
- Trial name
- ACHIEVE-LT (NCT07471165)
- Testing
- PD -1/PD-L1 monoclonal antibody plus radiotherapy and liver transplantation
- Where
- 2 sites in China
- Volunteers
- 25 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Cholangiocarcinoma Cancer, Perihilar Cholangiocarcinoma
Robotically Assisted Surgery For Perihilar Cholangiocarcinoma: A Prospective Study
Cholangiocarcinoma (CCA) represents the most common biliary tract malignancy, and the second most common primary hepatic malignancy, accounting for 15% to 20% of primary liver tumours.
- Trial name
- ROBOCHOL (NCT06720883)
- Testing
- Major hepatectomy
- Where
- Italy
- Volunteers
- 32 people
- Sponsor
- Azienda Ospedaliera di Padova
Perihilar Cholangiocarcinoma, Klatskin Tumor
Liver Transplantation for Non-resectable Perihilar Cholangiocarcinoma
The study will investigate whether liver transplantation provides increased survival, low side effects and good quality of life in patients with bile duct cancer where the tumor cannot be removed by normal surgery.
- Conditions
- Perihilar Cholangiocarcinoma, Klatskin Tumor, Bile Duct Cancer
- Trial name
- TESLA II (NCT04993131)
- Testing
- Liver transplant
- Where
- Norway
- Volunteers
- 15 people
- Sponsor
- Oslo University Hospital
Perihilar Cholangiocarcinoma
Minimally Invasive Versus Open Surgery for PHC
Brief Summary: This is a multicentric, retrospective, real-world study to investigate the surgical outcomes of minimally invasive surgery compared with open surgery for Perihilar Cholangiocarcinoma (PHC), with the perioperative…
- Trial name
- NCT05402618
- Testing
- No intervention
- Where
- China
- Volunteers
- 783 people
- Sponsor
- Renyi Qin
Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
This randomized phase II trial studies how well trametinib or combination chemotherapy works in treating patients with refractory or advanced biliary or gallbladder cancer or that cannot be removed by surgery.
- Conditions
- Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma, BCLC Stage C Adult Hepatocellular Carcinoma, BCLC Stage D Adult Hepatocellular Carcinoma
- Trial name
- S1310 (NCT02042443)
- Testing
- Capecitabine, Fluorouracil, Laboratory Biomarker Analysis
- Where
- 295 sites in United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Cholangiocarcinoma Non-resectable
Preoperative Right Hepatic Artery Embolization for Locally Advanced Bismuth IIIb and IV Perihilar Cholangiocarcinoma
This is a prospective, multicenter, single-arm study investigating the efficacy and safety of preoperative right hepatic artery embolization (PHAE) followed by surgical resection in patients with locally advanced Bismuth IIIb or…
- Trial name
- PHAE-PHCC (NCT07326189)
- Testing
- Preoperative Right Hepatic Artery Embolization
- Volunteers
- 33 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Klatskin Tumor
Stereotactic Body Radiation Therapy for Unresectable Perihilar Cholangiocarcinoma
Rationale: For patients with perihilar cholangiocarcinoma, surgery is the only treatment modality that can result in cure. Unfortunately, in the majority of these patients the tumors are found to be unresectable at presentation…
- Trial name
- STRONG (NCT03307538)
- Testing
- Stereotactic body radiation therapy
- Where
- Netherlands
- Volunteers
- 6 people
- Sponsor
- Erasmus Medical Center
Hilar Cholangiocarcinoma
Percutaneous Bilateral Versus Unilateral Metal Stent for Hilar Cholangiocarcinoma
Cholangiocarcinoma (CCA) is the most common biliary malignancy and the second most common hepatic malignancy after hepatocellular carcinoma (HCC).
- Trial name
- NCT02108145
- Testing
- bilateral metal stent insertion, unilateral metal stent insertion
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Air Force Military Medical University, China
Klatskin's Tumor
Photodynamic Therapy With Polyhematoporphyrin for Malignant Biliary Obstruction
Photodynamic therapy (PDT) is a palliative treatment for malignant biliary obstruction. The aim of this study is to assess the feasibility and safety of this technique in the context of a nationwide retrospective analysis.
- Trial name
- NCT02504957
- Testing
- Photodynamic therapy using polyhematoporphyrin
- Volunteers
- 88 people
- Sponsor
- Medical University of Vienna
Cholangiocarcinoma, Hilar Cholangiocarcinoma
Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma
This is a phase II, single-arm, prospective clinical trial designed to evaluate the efficacy and safety of neoadjuvant therapy combining stereotactic body radiotherapy (SBRT), GP chemotherapy (gemcitabine and…
- Conditions
- Cholangiocarcinoma, Hilar Cholangiocarcinoma, Bile Duct Cancer
- Trial name
- NCT07030140
- Testing
- Stereotactic Body Radiotherapy (SBRT), Tislelizumab, Gemcitabine
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Jinbo Yue
Non-Resectable Cholangiocarcinoma, Recurrent Cholangiocarcinoma
Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma
This phase Ib trial studies the side effects and best dose of ricolinostat when given together with gemcitabine hydrochloride and cisplatin in treating patients with cholangiocarcinoma that cannot be removed by surgery or has…
- Conditions
- Non-Resectable Cholangiocarcinoma, Recurrent Cholangiocarcinoma, Stage III Extrahepatic Bile Duct Cancer, Stage III Intrahepatic Cholangiocarcinoma
- Trial name
- NCT02856568
- Testing
- Cisplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Sponsor
- Mayo Clinic
Cholangiocarcinoma, Extrahepatic, Cholangiocarcinoma of the Extrahepatic Bile Duct
Raman Spectroscopy in the Diagnosis of Extrahepatic Cholangiocarcinoma - a Pilot Study
Diagnosis of extrahepatic cholangiocarcinoma is challenging because the yield of imaging and tissue sampling is limited. Raman spectroscopy is an optical method based on the analysis of scattered monochromatic light.
- Conditions
- Cholangiocarcinoma, Extrahepatic, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma, Perihilar, Diagnosis
- Trial name
- NCT06964425
- Testing
- Endoscopic retrograde cholangiopancreatography (ERCP)
- Where
- Czechia
- Volunteers
- 20 people
- Sponsor
- University Hospital Olomouc
Ampulla of Vater Adenocarcinoma, Gallbladder Adenocarcinoma
ADH-1, Gemcitabine Hydrochloride & Cisplatin in Treating Metastatic Pancreatic or Biliary Tract Cancer
This phase I trial studies the side effects and best dose of ADH-1 when given together with gemcitabine hydrochloride and cisplatin in treating patients with pancreatic or biliary tract cancer that has spread from where it…
- Conditions
- Ampulla of Vater Adenocarcinoma, Gallbladder Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT01825603
- Testing
- ADH-1, Cisplatin, Gemcitabine Hydrochloride
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Nebraska
Treatment Response, Adverse Events
Photodynamic Therapy in Locally Advanced Hilar Cholangiocarcinoma
To determine the safety and efficacy of photodynamic therapy with a novel photosensitizer and a flexible laser probe in locally advanced hilar cholangiocarcinoma.
- Conditions
- Treatment Response, Adverse Events, Feasibility
- Trial name
- PDT (NCT02725073)
- Testing
- Photodynamic therapy
- Where
- 2 sites in South Korea
- Volunteers
- 32 people
- Sponsor
- Asan Medical Center
Hilar Cholangiocarcinoma
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Photodynamic therapy (PDT) is a combination of a drug, porfimer sodium (Photofrin), which is activated by a light from a laser that emits no heat.
- Trial name
- NCT02082522
- Testing
- Photodynamic therapy-Photofrin, Stenting procedure, Chemotherapy regimen
- Where
- 31 sites in United States, Canada and 3 more
- Volunteers
- 28 people
- Sponsor
- Concordia Laboratories Inc.
Cholangiocarcinoma
Regorafenib Versus Placebo to Treat Cholangiocarcinoma
The study is a multicenter randomized (1:1) placebo-controlled, double-blinded phase II trial aiming to demonstrate an improvement of median PFS when treating locally advanced unresectable or metastatic patients suffering from an…
- Trial name
- REACHIN (NCT02162914)
- Testing
- Regorafenib/active
- Where
- 12 sites in Belgium
- Volunteers
- 66 people
- Sponsor
- Erasme University Hospital
Perihilar Cholangiocarcinoma
Endobiliary Radiofrequency Ablation for Malignant Biliary Obstruction Due to Perihilar Cholangiocarcinoma
A multicentre, parallel group, open label, randomized controlled trial comparing endobiliary RFA prior to metal stent placement with stent placement only in patients with inoperable perihilar cholangiocarcinoma.
- Trial name
- RACCOON (NCT05546372)
- Testing
- Endobiliary radiofrequency ablation (eRFA), uncovered self-expanding metal stent (uSEMS)
- Where
- Netherlands
- Volunteers
- 122 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Hilar Cholangiocarcinoma
Efficacy and Safety Study of PDT Using Deuteporfin for Unresectable Advanced Perihilar Cholangiocarcinoma
This is a multi-center, randomized, controlled, open-label, phase IIa clinical study.The study will observe the efficacy and safety of Deuteporfin photodynamic therapy in addition to stenting compared to stenting alone in…
- Trial name
- NCT02955771
- Testing
- PDT-Deuteporfin（6 hour), PDT-Deuteporfin（9 hour), stenting
- Where
- 4 sites in China
- Volunteers
- 7 people
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.